Therapeutics Hormonal Agents

Toxaemia of pregnancy treated with progesterone during the symptomatic stage

Dalton K

Published August 17, 1957 British Medical Journal, 2(5041), 378-381
DOI 10.1136/bmj.2.5041.378 PMID 13446488 PMC PMC1962072

RRM Academy Synopsis

Toxemia fell from 9% to 2.1% in one hospital's progesterone scheme

A 1957 report found that toxemia of pregnancy fell from 9% to 2.1% of deliveries once a progesterone scheme began. Women with early symptoms got progesterone or a related drug. Of 109 treated women, 5 developed toxemia.

Toxemia of pregnancy: Before the progesterone scheme, 9 in 100; After the progesterone scheme, 2.1 in 100
Toxemia of pregnancy: Before the progesterone scheme, 9 in 100; After the progesterone scheme, 2.1 in 100. Source: Dalton K, 1957, PMID 13446488.
Study at a glance, hospital case series: Toxemia fell from 9% to 2.1% of deliveries after a progesterone scheme
Study at a glance, hospital case series of 109 treated women: Toxemia fell from 9% to 2.1% of deliveries after a progesterone scheme. Source: Dalton K, 1957, PMID 13446488.

Key Findings

  • Before the scheme began in June 1955, toxemia averaged 9% across about 5,307 deliveries, with quarterly rates between 6.2% and 11%.
  • In the third quarter of 1955 the rate fell from 7.2% to 3.9%, then to 2.5%, 1.9%, 1.0% and 1.3% in the following quarters.
  • The author counted 12 deliveries for every toxemic patient before the scheme and 47.6 deliveries for every toxemic patient after it.
  • Of 109 patients treated with progesterone, 5 developed toxemia. Of 20 patients whose symptoms progesterone did not relieve, 1 developed toxemia.
  • Among 13 treated women who had gained 6 lb or more in the prior four weeks, weight gain was lower in the next four weeks in every one.

Interpretation

This hospital case series tracked toxemia rates before and after a progesterone scheme began in June 1955. The rate fell each quarter, from 9% down to 2.1%. The author called the work preliminary. She noted that low progesterone could be a key factor behind toxemia. The findings support larger studies of progesterone's role in toxemia of pregnancy.

RRM Context

Restorative Reproductive Medicine looks for the root cause of a complication. The author linked toxemia to low progesterone. She noted its early symptoms looked like PMS. Progesterone is the body's own hormone. The drug some women got instead, ethisterone, is a different substance.

Abstract

While investigating the use of progesterone for the relief of premenstrual syndrome (Greene and Dalton, 1953) a high incidence of toxaemia of pregnancy (19.1 %) was recognized among sufferers from this syndrome. A further investigation, undertaken to ascertain the incidence of premenstrual syndrome in those who had previously suffered from toxemia of pregnancy, revealed that 86% of the 237 women thus affected at one time or another during the previous twelve years also suffered from premenstrual syndrome (Dalton, 1954). Furthermore, direct questioning and a scrutiny of records of these patients showed that before the full development of the signs of toxaemia–that is, oedema, hypertension, and albuminuria–most had earlier in the pregnancy experienced a symptomatic stage characterized by relatively minor afflictions–for example, lethargy 43 %, headache 48%, visual aura 37%, vertigo 29%, nausea and vomiting 16%, irritability 14%, depression 9%, and backache 6%. In fact, only 7% disclosed freedom from these symptoms during a toxaemic pregnancy. Of the 237 women, 92 (38.8%) had experienced both a normal and a toxaemic pregnancy, and 72 (78 %) contrasted the sense of well-being associated with a normal pregnancy with the malaise and minor symptoms characteristic of the toxaemic condition.

The striking feature of these early minor symptoms of toxaemia was their close resemblance to those of premenstrual syndrome noted in an earlier investigation (Greene and Dalton, 1953), most patients confirming that the minor symptoms during their toxaemic pregnancy were similar, though of increased severity, to those experienced in the premenstruum, irrespective of whether the onset of premenstrual syndrome had preceded or followed the toxaemic pregnancy.

Apart from the similarities of these minor symptoms in the two conditions, other points in common were noted.

For example, day-to-day observations of sufferers of premenstrual syndrome had shown that, apart from minor symptoms, some developed oedema, hypertension, and albuminuria during the premenstruum, with spontaneous improvement during menstruation.

This appeared to be analogous to the spontaneous resolution of oedema, hypertension, and albuminuria following delivery. Furthermore, if symptoms remain untreated either in premenstrual syndrome or in toxaemia both diseases may culminate in fits, epileptic in the one case, eclamptic in the other.

In an earlier investigation one of the reasons for using progesterone in the treatment of premenstrual syndrome had been that some patients suffering from this condition were symptom-free during pregnancy. It was considered that the corpus luteum and placenta supplied enough progesterone during pregnancy to keep these patients symptom-free. Others were not only unrelieved of their premenstrual symptoms during pregnancy, but, as already indicated, developed symptoms closely resembling those of the premenstruum and culminating in toxaemia. It was therefore thought possible that the development of toxaemia might in such cases arise from failure of the corpus luteum and placenta to produce sufficient progesterone.

In the light of similarities between premenstrual syndrome and toxaemia, and the fact that treatment of the former with progesterone not only relieved the symptoms (Greene and Dalton, 1953) but also prevented the development of edema, hypertension, and albuminuria in the premenstruum (Dalton, 1954, 1955), it was decided to carry out a trial, employing large doses of progesterone in patients disclosing early minor symptoms of toxaemia, in an attempt to arrest full development of that condition.

Topics

By this author

Related research

Therapeutics › Hormonal Agents › Progesterone and Progestins · Menstrual Cycle › Premenstrual Disorders › Premenstrual Syndrome Treatment · Reproductive Endocrinology › Ovarian Hormones › Progesterone
PMID 13446488 13446488 DOI 10.1136/bmj.2.5041.378 10.1136/bmj.2.5041.378 Dalton et al. 1957, Dalton 1957